|
Adherence to oral therapies in metastatic castration resistance (m CRPC) prostate cancer patients: The ADOPTA study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Enrique González-Billalabeitia |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BMS Brazil; Ipsen; Janssen; MSD; Roche/Genentech; Sanofi |
Research Funding - Astellas Oncology |
Travel, Accommodations, Expenses - Astellas Oncology; Janssen Oncology |